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Abstract For the first time in the electron spin resonance (ESR)
and peptide synthesis fields, a fully active spin-labeled peptide
hormone was reported. The ESR spectra of this K-melanocyte
stimulating hormone (K-MSH) analogue (acetyl-Toac0-K-MSH)
where Toac is the paramagnetic amino acid probe 2,2,6,6-
tetramethylpiperidine-1-oxyl-4-amino-4-carboxylic acid, sug-
gested a pH-independent conformation and a more restricted
movement comparatively to the free Toac. Owing to its
equivalent biological potency in a skin pigmentation assay as
compared to the native K-MSH and its unique characteristic
(paramagnetic, naturally fluorescent and fully active), this
analogue is of great potential for investigation of relevant
physiological roles reported for K-MSH.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
The potentials of the ESR method in peptide chemistry and
biology have been the subject of our studies for many years.
The initial challenge was to ¢nd out a strategy to bind
through a peptide bond, a stable and paramagnetic compound
(spin label) into a peptide sequence. Thus, our introduction
into the realm of ESR application in peptide synthesis method
[1^3] initiated almost two decades ago [4] with the synthesis of
the 2,2,6,6-tetramethylpiperidine-1-oxyl-4-amino-4-carboxylic
acid (Toac) spin probe [5], see below, but protected in its
amino group with the acid labile tert-butyloxycarbonyl
(Boc) temporary
protecting group necessary for peptide chain assembly (Boc-
Toac). Unlike most spin-labeling strategies applied so far,
where long and £exible nitroxide-containing probes have
been routinely used [6,7], the Toac labeling is clearly more
advantageous. It binds more rigidly to the target molecule
as a consequence of its CK-tetrasubstituted cyclic structure,
where the rotation about side-chain bonds is hampered by
incorporation of the nitroxide nitrogen and CK, CL and CQ
atoms into the same heterocyclic moiety. Due to these char-
acteristics the probe is highly sensitive to conformational
states of the peptide backbone under study.
Hence, the Boc-Toac derivative was initially used for the
syntheses of two vasoactive peptide angiotensin II (AII) ana-
logues (Toac0- and Toac1-AII) but considerable AII activity
was lost after the structural alterations [8]. At that time, there
was no chemical strategy proposed to introduce the Toac
probe at internal positions of the peptide sequence. This
shortcoming was due to the irreversible degradation of the
nitroxide moiety of the Boc-Toac during the repeated tri-
£uoroacetic acid treatments necessary for removal of Boc
group from Toac and from other incoming amino acid resi-
dues for further peptide chain elongation with the Boc strat-
egy [1]. Only one decade later [9], we were able to propose an
alternative procedure using the base labile 9-£uorenylmeth-
yloxycarbonyl (Fmoc) group [2,3] for the Toac amino group
protection and conjugating both Fmoc (for peptide chain
elongation) and Boc (for peptide cleavage from the resin)
chemistries. Thus, the ¢rst synthesis of an internally contain-
ing spin probe peptide sequence was achieved with the Toac7-
AII [9], and more recently other vasoactive peptide (bradyki-
nin, BK) was also internally labeled [10]. However, both
Toac3-BK and Toac7-AII analogues were totally devoid of
biological activity, whereas the BK analogue labeled at the
N-terminus (Toac0-BK) maintained only a partial activity
[10]. Additionally, Toac has also been used to label: (i) a
seven transmembrane helix AII receptor fragment to investi-
gate its binding to lipid bilayers and micelles [11], (ii) model
peptide-resins to evaluate the peptide chain aggregation inside
beads during the synthesis [12]. Moreover, the special bend-
inducing property of the Toac molecule [13] has permitted in
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recent years the examination of helix-type conformational
properties of single and double Toac-labeled model peptide
sequences [14^16].
The next challenge concerning this spin-labeling approach
was therefore to demonstrate the feasibility of synthesizing
a Toac-containing active peptide that might retain its full
biological potency. The tridecapeptide K-melanocyte stimulat-
ing hormone, K-MSH [17] containing the sequence acetyl-Ser-
Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 was
chosen for the present labeling investigation. This important
hormone synthesized in the pituitary gland and skin of verte-
brates is involved, among a great variety of physiological
processes, in the skin darkening of most vertebrates, including
humans [18], erectile function [19] and satiety [20]. Several
modi¢cations of the K-MSH primary structure have yielded
reasonable elucidation of its structure-activity relationship
and the synthesis of a potent and long lasting analogue [21]
has been already reported. Owing mainly to its higher stabil-
ity, most of K-MSH-labeling studies with several markers
have been focused on this more potent analogue, with no
loss of biological activity [22,23]. Di¡erently, the present re-
port describes the ¢rst synthesis of a native K-MSH analogue,
labeled with the Toac spin probe (Ac-Toac0-K-MSH) and that
still retained its entire potency.
2. Materials and methods
2.1. Peptide synthesis [1^3]
The native K-MSH was synthesized in 0.1 mmol scale according to
the Boc chemistry and using methylbenzohydrylamine-resin
(MBHAR) and the following Boc amino acid derivatives: Bzl for
Ser, OcHex for Glu, 2-Br-Z for Lys, Tos for His and Arg. Couplings
were performed with Boc amino acid/TBTU/HOBt (1:1:1) compo-
nents in the presence of DIEA in NMP. The synthesized K-MSH
was cleaved from the resin with HF:o-cresol:DMS:EDT
(8.5:0.5:0.5:0.5, v/v) solution at 0‡C for 90 min. After evaporation,
the resin was washed with ethyl acetate, dried, and the peptide was
extracted into 5% acetic acid in water and lyophilized.
The Ac-Toac0-K-MSH synthesis followed almost the same protocol
applied for the native K-MSH but with some alterations as already
reported [9]. The introduction of the Toac probe was performed with
its Fmoc derivative, which was removed with the alkaline piperidine/
DMF (20%, v/v) treatment for 30 min. The acetylation of the Toac
amine group was done with acetic anhydride/DMF (1:4, v/v) solution
containing 0.1 ml of pyridine for 30 min. After HF cleavage, the crude
spin-labeled peptide was submitted to alkaline treatment (pH 10, for
6 h at 25‡C) for complete reversion (monitored by analytical HPLC)
of the N-O protonation that occurs during HF treatment.
Both peptides were puri¢ed in preparative HPLC (C18-column) us-
ing aqueous 0.02 M ammonium acetate (pH 5.0) and 60% MeCN
solutions as solvents A and B, respectively (linear gradient of 30^
70% B in 2 h, £ow rate of 10 ml/min). The homogeneity of both
peptides was con¢rmed through analytical HPLC, matrix-assisted la-
ser desorption ionization-mass spectrometry and amino acid analysis.
In this latter case, the Toac residue is not determined as it decomposes
during the acid hydrolysis.
2.2. Biological assays [24]
The thigh and dorsal skin of the frog was excised, cut in square
(2U2 cm2) pieces, which were placed between two PVC rings and kept
for 1 h in Ringer’s solution. After this period, the melanin granules
were aggregated in the perinuclear region of the melanocytes, which
assumed a punctuate state, and the skins become light. Upon addition
of K-MSH or the analogue to the medium, the pigment disperses out
into the dendritic processes of the cell, resulting in skin darkening.
The changes in skin color (decrease in skin re£ectance) were moni-
tored with a Photovolt re£ectometer and expressed as percent change
of the initial value. Dose-response curves and the EC50 (the concen-
tration eliciting 50% of the maximal darkening, con¢dence interval of
95%) were determined for both peptides.
3. Results and discussion
Knowing some of the structural requirements for K-MSH
biological activity, the Toac was inserted between the acetyl
group and the Ser1 residue out of the important 4^12 core of
its sequence [25]. The chemical strategy to obtain the Ac-
Toac0-K-MSH analogue involved a conjugation of Boc and
Fmoc chemistries as already mentioned [9]. The selection of
the solvent for the critical coupling reaction step amino acid
residues was based upon our recent peptidyl-resin solvation
strategy [26] where a novel solvent polarity parameter was
also proposed. The polar aprotic 1-methyl-2-pyrrolidinone
(NMP) swelled almost 80% of peptide-resin bead volume
throughout all chain assembly and was therefore used with
success for the synthesis of both peptides. After alkaline re-
version of the nitroxide moiety protonation that occurs during
HF cleavage of peptide from the resin and HPLC puri¢cation,
47 mg and 33 mg of pure K-MSH and Ac-Toac0-K-MSH were
obtained, respectively.
The frog (Rana catesbeiana) skin bioassay was performed in
vitro as previously described [24]. Ac-Toac0-K-MSH was a full
agonist on the frog melanocyte, promoting a dose-dependent
skin darkening (Fig. 1) with the same potency as the native K-
MSH. The concentration eliciting 50% of the maximal dark-
ening (EC50) and the con¢dence interval of 95% (CI) were for
the labeled analogue and the native hormone, respectively
2.70U10310 M (1.02^7.10) and 1.96U10310 M (0.72^5.34).
In addition, after removal of the agonist, and several Ringer’s
rinses, the reversal of the maximal response to Ac-Toac0-K-
MSH was achieved after 180 min, at the same rate exhibited
by K-MSH (Fig. 2). These results show, for the ¢rst time, that
the spin labeling of the native sequence of K-MSH was suc-
cessfully performed, full agonism being retained, with no loss
of potency as compared to the native hormone. It also means
that, in some circumstances, the most serious criticism of the
ESR method, i.e. the lack of meaning in studying a spin-la-
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Fig. 1. Dose-response curves to Ac-Toac0-K-MSH as compared to
the native K-MSH, in the frog Rana catesbeiana skin bioassay. Each
point represents the mean (n = 10) þ S.E.M. (standard error of the
mean) darkening response at the concentrations noted.
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beled system due to the introduction of a non-natural compo-
nent in its structure, may be not acceptable.
The ESR spectra demonstrate the di¡erent mobility of the
free and peptide-bound Toac (Fig. 3). Both compounds dis-
play narrow lines, as expected for small molecules tumbling in
a non-viscous solvent. However, the correlation times (d) for
K-MSH-bound Toac are one order of magnitude higher than
those obtained for free Toac (Table 1). The di¡erent rotation-
al correlation time dB and dC values obtained for the labeled
peptide and not for Toac indicate an anisotropic movement
[27] for the former. Preliminary results with Ac-Toac0-K-MSH
also suggest that its conformation does not depend on the pH
of the media, as its ESR parameters have not changed in acid
or alkaline solutions (Table 1). Moreover, equivalent isotropic
hyper¢ne parameter (a0) values indicate similar microenviron-
ment for Toac either free or bound to the peptide, at all pH
values.
In conclusion we herein described the ¢rst synthesis of a
fully active spin-labeled peptide hormone. The availability of
such unique analogue (Ac-Toac0-K-MSH) that is paramag-
netic, naturally £uorescent due to the tryptophan residue of
its structure and fully active, is clearly of great potential. Be-
sides the expected more complete ESR studies in solution, the
use of this paramagnetic peptide may allow for instance, the
inversion of the more common strategy used up to now for
peptide binding studies in membrane-mimetic systems. In the
place of spin labeling the lipid bilayer and evaluating the bind-
ing of the agonist, as already described for the K-MSH itself
[28], the labeling site is now located within the native hormone
structure as already reported with external fragments of some
seven transmembrane helix proteins [11,29]. The same ap-
proach would be also further extended for the approach [30]
which evaluates interaction features of transmembrane helix
segments with model membrane. Moreover, one can also si-
multaneously spin label both the agonist and the system under
study, for structure and binding investigation through the
assessment of spin-spin interactions phenomenon [31] that
may occur depending upon the average distance between
probes. The K-MSH binding assay to lipid bilayers has al-
ready been examined by £uorescence, monitoring the native
Trp9 residue of the hormone [32]. Complementarily, the use of
the paramagnetic hormone may provide an alternative route
to that investigation due to the well-known £uorescence
quenching e¡ect [33] of the nitroxide function. The secondary
structure of nicotinic acetylcholine receptor inside the mem-
brane was for instance investigated through the quenching
phenomenon [34]. Therefore, the use of this special quenching
agonist may be also valuable for further imaging and quanti-
¢cation studies of melanotropin binding to K-MSH recep-
tors present in normal melanocytes or melanoma cell lines
[35,36].
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Table 1
ESR data for Toac and Ac-Toac0-K-MSH
System a0 (G) dB (ns) dC (ns)
Toac
pH 5.0 16.32 0.036 0.036
Ac-Toac0-K-MSH
pH 3.0 16.29 0.324 0.396
pH 5.0 16.29 0.313 0.382
pH 9.0 16.26 0.305 0.372
The estimated errors in the values of a0 and d are around þ 0.03 G
and 0.005 ns, respectively. ESR measurements were performed at
25‡C with a Bruker EMX spectrometer. A ¢eld-modulation amplitude
of 0.5 G and microwave power of 5 mW was used. The temperature
was controlled to about 0.2‡C with a Bruker BVT-2000 variable tem-
perature device. The spectral parameters were found by ¢tting each
line to a Gaussian-Lorentzian sum function taking advantage of the
fact that the sum function is an accurate representation of a Gaussian-
Lorentzian convolution, the Voigt function [31]. The hyper¢ne split-
ting, a0, was taken to be one-half the di¡erence in the resonance ¢elds
of the high- and low-¢eld lines. The intrinsic (Lorentzian) line widths
and the line heights were determined from the ¢ts and rotational
correlation times, dB and dC were calculated [27].
Fig. 3. ESR spectra of 1034 M Toac and Ac-Toac0-K-MSH in aque-
ous solutions (pH 5.0).
Fig. 2. Reversal of the maximal responses to the native hormone
and to Ac-Toac0-K-MSH (1038 M) after removal of the peptides
and rinsing of the preparation (arrow). Each point is the mean
(n = 10) þ S.E.M., Rana catesbeiana skin darkening at the times
noted.
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